Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009 (2009), Article ID 369602, 5 pages
http://dx.doi.org/10.1155/2009/369602
Research Article

Differences in Transcriptional Activation by the Two Allelic (L162V Polymorphic) Variants of PPAR after Omega-3 Fatty Acids Treatment

1Lipid Research Center, CHUL Research Center, QC, Canada G1V 4G2
2Department of Food Science and Nutrition, Laval University, QC, Canada G1V 0A6
3Nutraceuticals and Functional Foods Institute (INAF), Laval University, QC, Canada G1V 0A6
4Laboratory of Molecular Pharmacology, Oncology and Genomic Research Center, CHUL Research Center, QC, Canada G1V 4G2
5Faculty of Pharmacy, Laval University, QC, Canada G1V 0A6

Received 22 August 2008; Revised 26 November 2008; Accepted 21 December 2008

Academic Editor: Mostafa Badr

Copyright © 2009 Iwona Rudkowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors a and ?,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar
  2. S. Kersten, “Peroxisome proliferator activated receptors and lipoprotein metabolism,” PPAR Research, vol. 2008, Article ID 132960, 11 pages, 2008. View at Publisher · View at Google Scholar
  3. E. L. Yong, J. Li, and M. H. Liu, “Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms α, β/δ and γ) and mechanisms of dyslipidemias,” Current Opinion in Lipidology, vol. 19, no. 2, pp. 106–112, 2008. View at Publisher · View at Google Scholar
  4. D. M. Flavell, I. Pineda Torra, Y. Jamshidi et al., “Variation in the PPARa gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects,” Diabetologia, vol. 43, no. 5, pp. 673–680, 2000. View at Publisher · View at Google Scholar
  5. E. S. Tai, S. Demissie, L. A. Cupples et al., “Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 805–810, 2002. View at Publisher · View at Google Scholar
  6. T. Tanaka, J. M. Ordovas, J. Delgado-Lista et al., “Peroxisome proliferator-activated receptor a polymorphisms and postprandial lipemia in healthy men,” Journal of Lipid Research, vol. 48, no. 6, pp. 1402–1408, 2007. View at Publisher · View at Google Scholar
  7. J. Uthurralt, H. Gordish-Dressman, M. Bradbury et al., “PPARa L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males,” BMC Medical Genetics, vol. 8, article 55, pp. 1–11, 2007. View at Publisher · View at Google Scholar
  8. T. Sparsø, M. S. Hussain, G. Andersen et al., “Relationships between the functional PPARa Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people,” Molecular Genetics and Metabolism, vol. 90, no. 2, pp. 205–209, 2007. View at Publisher · View at Google Scholar
  9. J. Robitaille, C. Brouillette, A. Houde et al., “Association between the PPARa-L162V polymorphism and components of the metabolic syndrome,” Journal of Human Genetics, vol. 49, no. 9, pp. 482–489, 2004. View at Publisher · View at Google Scholar
  10. E. S. Tai, D. Corella, S. Demissie et al., “Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study,” Journal of Nutrition, vol. 135, no. 3, pp. 397–403, 2005. View at Google Scholar
  11. A.-M. Paradis, B. Fontaine-Bisson, Y. Bossé et al., “The peroxisome proliferator-activated receptor a Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men,” American Journal of Clinical Nutrition, vol. 81, no. 2, pp. 523–530, 2005. View at Google Scholar
  12. A. Sapone, J. M. Peters, S. Sakai et al., “The human peroxisome proliferator-activated receptor a gene: identification and functional characterization of two natural allelic variants,” Pharmacogenetics, vol. 10, no. 4, pp. 321–333, 2000. View at Publisher · View at Google Scholar
  13. N. Vu-Dac, K. Schoonjans, V. Kosykh et al., “Retinoids increase human apolipoprotein A-II expression through activation of the retinoid X receptor but not the retinoic acid receptor,” Molecular and Cellular Biology, vol. 16, no. 7, pp. 3350–3360, 1996. View at Google Scholar
  14. E. Jungling and H. Kammermeier, “A one-vial method for routine extraction and quantification of free fatty acids in blood and tissue by HPLC,” Analytical Biochemistry, vol. 171, no. 1, pp. 150–157, 1988. View at Publisher · View at Google Scholar
  15. H. S. Simpson, C. M. Williamson, T. Olivecrona et al., “Postprandial lipemia, fenofibrate and coronary artery disease,” Atherosclerosis, vol. 85, no. 2-3, pp. 193–202, 1990. View at Publisher · View at Google Scholar
  16. J. M. Peters, N. Hennuyer, B. Staels et al., “Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor a-deficient mice,” The Journal of Biological Chemistry, vol. 272, no. 43, pp. 27307–27312, 1997. View at Publisher · View at Google Scholar
  17. P. Costet, C. Legendre, J. Moré, A. Edgar, P. Galtier, and T. Pineau, “Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis,” The Journal of Biological Chemistry, vol. 273, no. 45, pp. 29577–29585, 1998. View at Publisher · View at Google Scholar
  18. C. Duval, M. Müller, and S. Kersten, “PPARα and dyslipidemia,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 961–971, 2007. View at Publisher · View at Google Scholar
  19. V. Zoete, A. Grosdidier, and O. Michielin, “Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 915–925, 2007. View at Publisher · View at Google Scholar
  20. M. H. Liu, J. Li, P. Shen, B. Husna, E. S. Tai, and E. L. Yong, “A natural polymorphism in peroxisome proliferator-activated receptor-α hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin,” Molecular Endocrinology, vol. 22, no. 5, pp. 1078–1092, 2008. View at Publisher · View at Google Scholar
  21. D. Caron-Dorval, P. Paquet, A.-M. Paradis et al., “Effect of the PPAR-alpha L162V polymorphism on the cardiovascular disease risk factor in response to n-3 polyunsaturated fatty acids,” Journal of Nutrigenetics and Nutrigenomics, vol. 1, no. 4, pp. 205–212, 2008. View at Publisher · View at Google Scholar
  22. E. M. Balk, A. H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau, “Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review,” Atherosclerosis, vol. 189, no. 1, pp. 19–30, 2006. View at Publisher · View at Google Scholar
  23. W. S. Harris, “n-3 fatty acids and serum lipoproteins: human studies,” American Journal of Clinical Nutrition, vol. 65, no. 5, pp. 1645S–1654S, 1997. View at Google Scholar
  24. S.-H. Wong, E. A. Fisher, and J. B. Marsh, “Effects of eicosapentaenoic and docosahexaenoic acids on apoprotein B mRNA and secretion of very low density lipoprotein in HepG2 cells,” Arteriosclerosis, vol. 9, no. 6, pp. 836–841, 1989. View at Google Scholar
  25. Y. Kobatake, K. Kuroda, and H. Jinnouchi, “Differential effects of dietary eicosapentaenoic and docosahexaenoic fatty acids on lowering of triglyceride and cholesterol levels in the serum of rats on hypercholesterolemic diet,” Journal of Nutritional Science and Vitaminology, vol. 30, no. 4, pp. 357–372, 1984. View at Google Scholar
  26. N. Willumsen, S. Hexeberg, J. Skorve, M. Lundquist, and R. K. Berge, “Docosahexaenoic acid shows no triglyceride-lowering effects but increases the peroxisomal fatty acid oxidation in liver of rats,” Journal of Lipid Research, vol. 34, no. 1, pp. 13–22, 1993. View at Google Scholar
  27. I. Ikeda, K. Wakamatsu, A. Inayoshi, K. Imaizumi, M. Sugano, and K. Yazawa, “α-linolenic, eicosapentaenoic and docosahexaenoic acids affect lipid metabolism differently in rats,” Journal of Nutrition, vol. 124, no. 10, pp. 1898–1906, 1994. View at Google Scholar
  28. I. Ikeda, J.-Y. Cha, T. Yanagita et al., “Effects of dietary a-linolenic, eicosapentaenoic and docosahexaenoic acids on hepatic lipogenesis and ß-oxidation in rats,” Bioscience, Biotechnology and Biochemistry, vol. 62, no. 4, pp. 675–680, 1998. View at Publisher · View at Google Scholar
  29. G. S. Rambjør, A. I. Wålen, S. L. Windsor, and W. S. Harris, “Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans,” Lipids, vol. 31, no. 1, pp. S45–S49, 1996. View at Publisher · View at Google Scholar
  30. S. Grimsgaard, K. H. Bønaa, J.-B. Hansen, and A. Nordøy, “Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids,” American Journal of Clinical Nutrition, vol. 66, no. 3, pp. 649–659, 1997. View at Google Scholar
  31. L. M. Sanderson, P. J. de Groot, G. J. E. J. Hooiveld et al., “Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics,” PLoS ONE, vol. 3, no. 2, p. e1681, 2008. View at Publisher · View at Google Scholar
  32. H. M. de Vogel-van den Bosch, M. Bünger, P. J. de Groot, H. Bosch-Vermeulen, G. J. E. J. Hooiveld, and M. Müller, “PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression,” BMC Genomics, vol. 9, article 231, pp. 1–13, 2008. View at Publisher · View at Google Scholar